About Knome
Knome is a Healthcare company based in Cambridge (United States) founded in 2007, and was acquired by Tute Genomics in November 2015. Human genome interpretation software and services are provided. It operates on a SaaS (Software-as-a-Service) and Professional Services model. Knome has raised $25 million across 5 funding rounds from investors including Tute Genomics. The company has 18 employees. Knome offers products and services including knoSYS and knomeDISCOVERY. Its focus areas include Biotechnology and Genomic Analysis. Its legal entity is Knome Inc. Its competitors include DNAnexus, Seven Bridges Genomics and Ingenuity Systems; 3 of its 3 listed competitors have raised funding.
Company details
Knome is involved in delivering bioinformatics infrastructure and insights for translational genomics initiatives. The company supports clinical NGS testing programs through scalable informatics systems like knoSYS for genome and exome data analysis. Additionally, research services such as knomeDISCOVERY are offered to pharmaceutical and academic researchers for studying large-scale human genomic data. Solutions are tailored to empower partners in advancing pharmaceutical success across healthcare and biotechnology sectors.
- Headquarters Cambridge, United States
- Employees 18
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website knome.com
- Social LinkedIn X
- Acquired by Tute Genomics (Nov 2015)
- Legal Name Knome Inc.
- Total Equity Funding$25M (USD)
in 5 rounds
- Latest Funding Round$13M (USD), Series B
Jan 2014
- Investors
- Employee Count18
- Acquired byTute Genomics
(Nov 2015)
Products & Services of Knome
Knome offers a comprehensive portfolio of products and services, including knoSYS and knomeDISCOVERY.
A system for analyzing and interpreting genomic data.
End-to-end solution for studying human genomic data.
Funding Insights of Knome
Knome has successfully raised a total of $25M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $13 million completed in January 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $25M
- Total Rounds 5
- Last Round Series B — $13M
- First Round $2M
(Nov 2008)
All 5 funding rounds of Knome with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2014 | $13M | Series B | – | – | – |
| Oct 2013 | $5.75M | Debt – Conventional | – | – | – |
| Jul 2011 | $5M | Series A | – | – | – |
| Apr 2010 | $5M | Series A | – | – | – |
| Nov 2008 | $2M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Knome
Knome has secured backing from 1 investor. Prominent investors backing the company include Tute Genomics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Cloud-based genome analysis for precision medicine is provided. | 2012 | tutegenomics.com | Los Angeles, United States |
Investor details for Knome
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Knome
4 dated milestones of Knome across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Knome is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series B, of $13.0M.
- Exit Acquired by Tute Genomics.
Competitors of Knome
Knome has 3 listed competitors in our database, 3 of them funded. They include DNAnexus, Seven Bridges Genomics and Ingenuity Systems.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| dnanexus.com | 2009 | Mountain View, United States | $472.55M | 143 | Cloud-based genome informatics and data management are provided. | |
| sevenbridges.com | 2009 | Cambridge, United States | $113M | 112 | Cloud-based platform to analyze, store, and act on genomic data. | |
| ingenuity.com | 1998 | Redwood, United States | $20.4M | 30 | Genomic data is analyzed and interpreted via web-based applications. |
Detailed competitors of Knome
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Knome
The website of Knome (knome.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▼ 34.5% vs previous month
Websites whose visitors overlap most with Knome. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| completegenomics.com | 100% | 11.4K | #2,001,051 | View details | |
| decode.com | 100% | 13.6K | #1,966,785 | View details | |
| navigenics.com | 100% | View details | |||
| 23andme.com | 99% | 4.4M | #8,883 | View details | |
personalgenomes.org | personalgenomes.org | 99% | #14,523,702 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 10 similar websites and full traffic analytics for Knome
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Knome (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Knome
Knome was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Knome is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Knome is a funded company, having raised a total of $25M across 5 funding rounds to date. The company's 1st funding round was a Series A of $2M, raised on Nov 2008.
Knome has 18 employees.
Knome is involved in delivering bioinformatics infrastructure and insights for translational genomics initiatives. The company supports clinical NGS testing programs through scalable informatics systems like knoSYS for genome and exome data analysis. Additionally, research services such as knomeDISCOVERY are offered to pharmaceutical and academic researchers for studying large-scale human genomic data. Solutions are tailored to empower partners in advancing pharmaceutical success across healthcare and biotechnology sectors.
Knome's top competitors include DNAnexus, Ingenuity Systems and Seven Bridges Genomics.
Knome offers knoSYS and knomeDISCOVERY.
Knome has 1 investor. Key investors include Tute Genomics.
Knome operates through Knome Inc..
Yes. Knome was acquired by Tute Genomics in November 2015.